Alexandra Langlais nackt sorted by
relevance

Admin02.07.2021

France: Langlais, Alexandra

The median OS from randomisation was 14.
2709
Admin06.08.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

YAP silencing decreased invasion of MST1-depleted mesothelial cell lines.
9906
Admin08.08.2021

France: Langlais, Alexandra

5 months median OS versus 19.
1308
Admin27.06.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
2809
Admin06.07.2021

Mesothelioma: Langlais, Alexandra

8 Department of Pneumology, Thoracic Oncology and Respiratory Intensive Care, Rouen University Hospital, 76000 Rouen, France.
1000
Admin26.06.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Patients were assessed consecutively during a 1-year period from April, 2012, to April, 2013.
8201
Admin19.07.2021

France: Langlais, Alexandra

received grants from Roche Diagnostics.
9409
Admin20.06.2021

France: Langlais, Alexandra

The academic clinical trials sponsored by the Cancer Cooperative Groups represented an important part of the research activity of the investigators in France in 2014.
701
Admin02.09.2021

France: Langlais, Alexandra

7 Thoracic Oncology Unit, CHU Grenoble Alpes, 38700 Grenoble, France.
9304
Admin01.09.2021

Mesothelioma: Langlais, Alexandra

RESULTS: PD-L1 staining was assessed in 214 47.
5401
Admin11.08.2021

France: Langlais, Alexandra

Nationally, however, the feasibility and effects on outcomes of this policy are unknown.
6705
Admin20.07.2021

Mesothelioma: Langlais, Alexandra

15 Service de Pneumologie, Centre Hospitalier, 194 Avenue Rubillard, 72037 Le Mans, France.
5106